GH Research (NASDAQ:GHRS) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of GH Research (NASDAQ:GHRS - Free Report) in a research note released on Thursday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $14.00 price target on the stock.

GHRS has been the subject of a number of other reports. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of GH Research in a report on Monday, January 27th. Canaccord Genuity Group dropped their target price on shares of GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, November 18th.

GH Research Stock Performance

NASDAQ GHRS remained flat at $14.31 during midday trading on Thursday. 126,242 shares of the company's stock traded hands, compared to its average volume of 986,893. The firm has a market cap of $744.55 million, a PE ratio of -18.11 and a beta of 0.93. The stock has a fifty day moving average of $9.62 and a two-hundred day moving average of $9.12. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50.

Institutional Investors Weigh In On GH Research

Institutional investors have recently modified their holdings of the business. AdvisorShares Investments LLC grew its position in shares of GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after buying an additional 4,806 shares during the period. Northern Trust Corp increased its position in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after acquiring an additional 8,641 shares in the last quarter. Geode Capital Management LLC increased its position in shares of GH Research by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after acquiring an additional 3,092 shares in the last quarter. Diadema Partners LP acquired a new position in GH Research during the fourth quarter worth $711,000. Finally, Lynx1 Capital Management LP boosted its holdings in GH Research by 15.8% during the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock worth $34,013,000 after purchasing an additional 663,100 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).